H.R. 9418 · Where this bill is now
In committee
Introduced in the House, sent to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned, Jun 24, 2026
What this bill does
In plain words · AI-written from the official summarySpeeds up Medicare drug coverage reviews
When Medicare denies or limits coverage for a drug that the FDA has approved, this bill requires Medicare to review that decision within 30 days if asked. It also prevents Medicare from using old coverage decisions made before a drug was officially approved by the FDA if those old decisions contradict the drug's current FDA approval. Medicare won't have to do a new review if it already reviewed the same drug's coverage within the past two years.
How it affects you
If you're on Medicare and your doctor prescribes a drug that Medicare initially won't cover, this bill could speed up how quickly Medicare reconsiders that denial. You'd potentially get access to approved medications faster, though whether Medicare ultimately covers any particular drug still depends on their review.
Read the official summary (Introduced in House, Jun 24, 2026)
Access to Innovative Treatments Act of 2026
This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.
Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.
The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
Written by AI (Claude) using only the official summary by the Congressional Research Service, the Library of Congress’s nonpartisan research staff. It can miss nuance, so check the official summary and the bill text for details.
2nd SessionH. R. 9418
A BILL
Access to Innovative Treatments Act of 2026
Sponsor: Rep. Nanette Diaz Barragán (D-CA-44) · Introduced Jun 24, 2026 · Health · 1 version of the text
Sources: Congress.gov actions and votes · bill text from GovInfo · latest official action Jun 24, 2026: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.”